In two ALK-positive male adult NSCLC patients developing brain metastases, crizotinib CSF/total serum concentration ratio was 0.06% and 0.1%, corresponding to CSF/unbound serum concentration ratios of 0.66% and 1.1%, respectively [71]. Here, ALK is linked to non-small cell lung carcinoma.